The market for laboratory-developed tests (LDTs) is evolving as the result of a mix of technological, financial, and regulatory factors. Broad technology platform shifts are underway. Serological and molecular diagnostic tests are becoming less popular as newer genomic and mass spectrophotometry (MS)–based tests are introduced. BCC Research has also observed that large national and regional reference laboratories are performing more LDTs, while smaller or academic laboratories reduce their testing volumes. High capital costs and low rates of reimbursement are hindering the efforts of smaller laboratories to keep pace with their larger counterparts.
There is a growing need for the treatment or prevention of tropical diseases. Neglected tropical diseases are a significant cause of death and morbidity among affected communities worldwide. According to BCC Research, the total global addressable market for these diseases (see Table) was $1.4 billion in 2015. This market is projected to grow at a compound annual growth rate (CAGR) of 14.1% to surpass $2.6 billion by 2021. BCC Research’s study, Global Markets for Neglected Tropical Disease Treatments, found that some indications (such as the Ebola and Zika viruses) are resulting in double-digit sales growth, whereas others face declining investment.
Single-use technology plays a pivotal role in the expanding biopharmaceutical industry. Trends in biopharmaceuticals are benefiting the global market for single-use systems and products, accelerating their manufacture and consumption. A recent study by BCC Research forecasts expansion at a five-year compound annual growth rate (CAGR) of 12.3% in the United States and 9.2% in Europe. Overall, the global market for single-use technology is estimated to reach $4.3 billion by 2021.
Wearable devices, which use biosensors to detect and monitor changes as well as capture physiological data, are primarily used in medical and fitness applications. The collection and analysis of data generated by wearables could also be applied to personalized medicine. Proponents believe that linking such sensors to smartphones will eventually be an integral part of achieving that goal. In addition, software platforms must be developed to integrate the output from sensors with genomic data and conventional medical information. Researchers hope that the merged data will result in signatures that can predict disease and help tailor treatments to each patient.